
Please try another search
MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Name | Age | Since | Title |
---|---|---|---|
Ramnik Xavier | 60 | 2022 | Independent Director |
Jorge Santos da Silva | 45 | 2021 | Co-Founder, CEO & Director |
Andrew J. Phillips | 51 | 2022 | Independent Director |
Simon J. Sturge | 64 | 2021 | Independent Chairman of the Board |
Spike Loy | 43 | 2021 | Independent Director |
Catherine Moukheibir | 64 | - | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review